Abstract:BackgroundThe congenital disorder of glycosylation associated with ALG1 (ALG1-CDG) is a rare autosomal recessive disease. Due to the deficiency of beta 1,4 mannosyltransferase caused by pathogenic variants in ALG1 gene, the assembly and processing of glycans in the protein glycosylation pathway are impaired, resulting in a broad clinical spectrum with multi-organ involvement. To raise awareness of clinicians for its manifestations and genotype, we here reported a new patient with a novel variant in ALG1 gene and reviewed the literature to study the genotype-phenotype correlation. MethodClinical characteristics were collected, and clinical exome sequencing was used to identify the causative variants. MutationTaster, PyMol, and FoldX were used to predict the pathogenicity, changes in 3D model molecular structure of protein, and changes of free energy caused by novel variants. ResultsThe proband was a 13-month-old Chinese Han male characterized by epileptic seizures, psychomotor development delay, muscular hypotonia, liver and cardiac involvement. Clinical exome sequencing revealed the biallelic compound heterozygosity variants, a previously reported variant c.434G>A (p.G145N, paternal) and a novel variant c.314T>A (p.V105N, maternal). The literature review found that in severe phenotypes, the incidences of clinical manifestations were significantly higher than that in mild phenotypes, including congenital nephrotic syndrome, agammaglobulinemia, and severe hydrops. Homozygous c.773C>T was a strongly pathogenic variant associated with a severe phenotype. When heterozygous for c.773C>T, patients with another variant leading to substitution in amino acids within the strongly conserved regions (c.866A>T, c.1025A>C, c.1182C>G) may cause a more severe phenotype than those within less-conserved regions (c.434G>A, c.450C>G, c.765G>A, c.1287T>A). c.1129A>G, c.1076C>T, and c.1287T>A were more likely to be associated with a mild phenotype. The assessment of disease phenotypes requires a combination of genotype and clinical manifestations. ConclusionsThe case reported herein adds to the mutations identified in ALG1-CDG and a review of this literature expands the study of the phenotypic and genotypic spectrum of this disorder.

Deficient glycan extension and endoplasmic reticulum stresses in ALG3‐CDG

ALG9-CDG: New Clinical Case and Review of the Literature

Dysregulated proteome and N‐glycoproteome in ALG1‐deficient fibroblasts

Normal transferrin glycosylation does not rule out severe ALG1 deficiency

A Novel N-Tetrasaccharide In Patients With Congenital Disorders Of Glycosylation, Including Asparagine-Linked Glycosylation Protein 1, Phosphomannomutase 2, And Mannose Phosphate Lsomerase Deficiencies

Case report: Novel genotype of ALG2-CDG and confirmation of the heptasaccharide glycan (NeuAc-Gal-GlcNAc-Man2-GlcNAc2) as a specific diagnostic biomarker

ALG13 X‐linked intellectual disability: New variants, glycosylation analysis, and expanded phenotypes

Wide clinical spectrum in ALG8-CDG: clues from molecular findings suggest an explanation for a milder phenotype in the first-described patient

Insufficient ER-stress response causes selective mouse cerebellar granule cell degeneration resembling that seen in congenital disorders of glycosylation

Comparative proteomics reveals elevated CCN2 in NGLY1-deficient cells

A Novel Variant in ALG1 Gene Associated with Congenital Disorder of Glycosylation: A Case Report and Short Literature Review.

Updated Clinical and Glycomic Features of Mannosyl-Oligosaccharide Glucosidase Deficiency: Two Case Reports

(Key1-001) congenital disorders of glycosylation: Glycobiology at the bedside

N-glycoproteomic and proteomic alterations in SRD5A3-deficient fibroblasts

Identification of two novel variants in ALG11 causing congenital disorder of glycosylation

Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation

Long-term outcomes in ALG13-Congenital Disorder of Glycosylation

Congenital Disorders of Glycosylation from a Neurological Perspective

Congenital disorders of glycosylation with multiorgan disruption and immune dysregulation caused by compound heterozygous variants in MAN2B2

A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity

Review and metabolomic profiling of unsolved case reveals newly reported autosomal dominant congenital disorder of glycosylation, type Iw formerly thought to only be an autosomal recessive condition